Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

Roivant Sciences is hoping for a big year. Earlier this month, the company revealed positive data for an inflammatory bowel disease drug it’s developing with Pfizer, positioning it as a competitor to a closely watched medicine from rival Prometheus Biosciences.